Fig. 4
Influence of KATP antagonist and mPTP opener on the protective effects of theaflavin against myocardial ischemia/reperfusion injury (measured after 60 min of reperfusion, n = 6 in each group). CON control group, TF1 theaflavin group (20 μmol/l), GLI glibenclamide group, 5-HD 5-hydroxydecanoate group, ATRA atractyloside group. a LVDP, b LVEDP, c +LVdp/dt max, d −LVdp/dt max, e CF. *P < 0.05, **P < 0.01 versus CON group; # P < 0.05, ## P < 0.01 versus TF1 group; + P<0.05 versus GLI group